Mineralys Therapeutics Inc (NASDAQ: MLYS) started the day on Thursday, with a price decrease of -6.09% at $31.38, before settling in for the price of $33.42 at the close. Taking a more long-term approach, MLYS posted a 52-week range of $8.24-$47.65.
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -170.42%. Meanwhile, its Annual Earning per share during the time was -170.42%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 35.15%. This publicly-traded company’s shares outstanding now amounts to $78.97 million, simultaneously with a float of $56.38 million. The organization now has a market capitalization sitting at $2.48 billion.
Mineralys Therapeutics Inc (MLYS) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Mineralys Therapeutics Inc’s current insider ownership accounts for 28.76%, in contrast to 79.81% institutional ownership. According to the most recent insider trade that took place on Jan 14 ’26, this organization’s Chief Medical Officer sold 11,367 shares at the rate of 32.61, making the entire transaction reach 370,645 in total value, affecting insider ownership by 50,437. Preceding that transaction, on Jan 13 ’26, Company’s Chief Medical Officer sold 7,709 for 32.75, making the whole transaction’s value amount to 252,470. This particular insider is now the holder of 61,804 in total.
Mineralys Therapeutics Inc (MLYS) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.54 per share during the current fiscal year.
Mineralys Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 35.15% and is forecasted to reach -2.19 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 11.46% through the next 5 years, which can be compared against the -170.42% growth it accomplished over the previous five years trading on the market.
Mineralys Therapeutics Inc (NASDAQ: MLYS) Trading Performance Indicators
Let’s observe the current performance indicators for Mineralys Therapeutics Inc (MLYS). It’s Quick Ratio in the last reported quarter now stands at 25.50.
In the same vein, MLYS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.96, a figure that is expected to reach -0.52 in the next quarter, and analysts are predicting that it will be -2.19 at the market close of one year from today.
